Where does AgomAb's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across AgomAb's 1 recorded funding rounds.

Premier Alternatives

AgomAb

Drug Discovery · Antwerp, Belgium · Founded 2017 · Privately Held (backing)

Developer of fibrotic disease treatments intended to preserve and restore organ function in fibrotic. AgomAb is based in Antwerp, Belgium and was founded in 2017. Its last known valuation is $416 million. It has raised $334 million across 1 recorded round; the latest was a $101 million Series C in Oct 2023.

Last price · $/share

—

Implied valuation

$415.6M

Total raised

$334.0M

Last round

Later Stage VC (Series C)

Oct 2023

Cap table — not yet on record

AgomAb's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of AgomAb with a free account

·The complete investor list: 17 names
·Watch AgomAb: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Frequently asked about AgomAb

Where does AgomAb's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across AgomAb's 1 recorded funding rounds.